INSMED INCORPORATED
INSM · NASDAQ
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United Statesand the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europeand in Japan. .
Market Data
Price
$136.33
+1.30 (+0.96%)
Market Cap$29.44B
P/E Ratio—
EPS$—
52W High$212.75
52W Low$63.81
Beta0.92
Data from Finnhub · Updated May 1, 2026